Despite soaring demand for GLP-1s, many eligible patients are unable to access these drugs for weight loss
In just a few short years, glucagon-like peptide-1 (GLP-1) receptor agonists have surged in popularity across the United States, transforming from specialized treatments for type 2 diabetes into revolutionary therapeutics for weight management, cardiovascular health and other emerging uses. But not all populations are benefiting from this expansion. As GLP-1 use has increased, disparities in…
Read original article on Medical Xpress - latest medical and health news stories →